Molecular Partners' Novel CD3 Switch-DARPin Platform To Be Highlighted At SITC 2024 With Proof-Of-Concept Data
Molecular Partners' Novel CD3 Switch-DARPin Platform To Be Highlighted At SITC 2024 With Proof-Of-Concept Data
Molecular Partners的新型CD3交換機-DARPin平台將在海豐國際2024年展示,展示概念數據。
- Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors
- Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation
- 在固體腫瘤中,47海豐國際橋蛋白技術平台支持CD3交換機-雲計算和具有增強功能的T細胞結合物的臨床前概念數據
- 已完成的MP0317(FAP x CD40)一期研究的生物標誌數據顯示預期和顯著的腫瘤微環境調節